Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical laboratory analysis"
DOI: 10.1002/jcla.24891
Abstract: BACKGROUND It is advised to pretreat the reagent erythrocytes with Dithiothreitol (DTT) to denature the surface CD38 to prevent anti-CD38 monoclonal antibodies (MoAb) from interfering with the blood compatibility test. Anti-CD38 has little impact on… read more here.
Keywords: anti cd38; polybrene; dtt iat; cd38 ... See more keywords
PCN183 Global Incidence, Prevalence, and Survival in Relapsed/Refractory (R/R) Adult Acute Lymphoblastic Leukemia (aALL): A Systematic Literature Review (SLR)
Sign Up to like & getrecommendations! Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.320
Abstract: and resource allocation decisions. This study aimed to assess the number of US patients with MM by LOT in 2020. Methods: Differential equations were used to develop a five-compartment model: LOT1–LOT5+. Patients in LOT1–LOT4 could… read more here.
Keywords: lot; treatment; model; prevalence ... See more keywords
PCN185 Treatment Patterns in Advanced Esophageal Squamous CELL Carcinoma (ESCC) Patients in Spain
Sign Up to like & getrecommendations! Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.322
Abstract: and resource allocation decisions. This study aimed to assess the number of US patients with MM by LOT in 2020. Methods: Differential equations were used to develop a five-compartment model: LOT1–LOT5+. Patients in LOT1–LOT4 could… read more here.
Keywords: lot; treatment; model; cell ... See more keywords
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Sign Up to like & getrecommendations! Published in 2022 at "Hematology"
DOI: 10.1080/16078454.2022.2028978
Abstract: Objectives: Daratumumab is the first anti-CD38 monoclonal antibody (Mab) used to treat myeloma in the newly diagnosed setting and in the relapsed setting. Isatuximab, another Mab targeting a specific epitope on the CD38 receptor, was… read more here.
Keywords: myeloma patients; two patients; daratumumab; case series ... See more keywords
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.14241
Abstract: This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 antibody TAK‐079. read more here.
Keywords: antibody tak; pharmacodynamics anti; tak 079; tolerability pharmacokinetics ... See more keywords
Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18714
Abstract: Multiple myeloma (MM) and anti‐MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID‐19) and other infections. We investigated anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) antibodies longitudinally in ultra‐high‐risk patients with MM… read more here.
Keywords: anti cd38; ultra high; high risk; risk ... See more keywords
Papain‐treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti‐CD38‐based therapies
Sign Up to like & getrecommendations! Published in 2018 at "Transfusion Medicine"
DOI: 10.1111/tme.12508
Abstract: To report our 2 years of experience navigating the interference of anti‐CD38 monoclonal antibodies (MAs) in 33 patients and describe papain‐treated panels as a complementary method to dithiothreitol (DTT). read more here.
Keywords: treated panels; papain treated; panels simple; simple method ... See more keywords
How do I work up pretransfusion samples containing anti‐CD38?
Sign Up to like & getrecommendations! Published in 2017 at "Transfusion"
DOI: 10.1111/trf.14144
Abstract: Anti‐CD38 is used to treat relapsed or treatment‐refractory multiple myeloma. CD38 monoclonal antibodies, however, can interfere with routine blood bank serologic tests. Agglutination is observed at the indirect phase of testing as the drug binds… read more here.
Keywords: work pretransfusion; pretransfusion samples; cd38; samples containing ... See more keywords
Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti‐idiotype antibody
Sign Up to like & getrecommendations! Published in 2022 at "Transfusion"
DOI: 10.1111/trf.17006
Abstract: Anti‐CD38 antibodies such as daratumumab (DARA) are critical therapies for multiple myeloma and other diseases. Unfortunately, anti‐CD38 antibodies cause panreactivity in indirect antiglobulin tests (IATs), complicating blood compatibility testing. The anti‐CD38 interference is most often… read more here.
Keywords: idiotype antibody; anti idiotype; anti cd38; antibody ... See more keywords
Mitigation of therapeutic anti‐CD38 antibody interference with fab fragments: How well does it perform?
Sign Up to like & getrecommendations! Published in 2023 at "Transfusion"
DOI: 10.1111/trf.17253
Abstract: Administration of anti‐CD38 antibodies is a state‐of‐the‐art therapy for patients diagnosed with multiple myeloma (MM). However, this treatment frequently leads to pan‐agglutination of red blood cells (RBCs) in patients' serological testing making accurate blood typing… read more here.
Keywords: anti cd38; cd38 antibody; interference fab; antibody interference ... See more keywords
Abstract 561: Discovery of a potential best-in-class anti-CD38 therapeutic utilizing Fc multimerization
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-561
Abstract: CD38 targeting antibodies are at different phases of clinical development, with daratumumab already approved as monotherapy and in combination with standards of care in multiple myeloma (MM). Anti-CD38 monoclonal antibodies (mAbs) induce tumor cell depletion… read more here.
Keywords: sifbody; multimerization; cd38; cell ... See more keywords